公司資料
UroGen Pharma 股價、新聞與催化劑
- 股票代碼:
- URGN
- 交易所:
- NASDAQ
- 產業:
- Biopharma
- 所在地:
- Israel with U
股票表現
49.14 USD (+1.91%)
收盤價
最後更新: 2026年8月17日
1.29B USD
市值
股價為何變動
The latest company update was “UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC”. URGN changed 1.91% and closed at $49.14 on Aug 17, 2026, indicating a relatively limited closing-price reaction to this company update.
公司概覽
Uro-Oncology Franchise
UroGen Pharma develops and commercializes treatments for urothelial and other specialty cancers. Its approach combines local drug delivery with formulations intended to extend exposure within the urinary tract and provide non-surgical alternatives for patients with recurrent disease.
Commercial ZUSDURI Platform
ZUSDURI is FDA approved for adults with recurrent low-grade, intermediate-risk non-muscle invasive bladder cancer. The intravesical mitomycin product uses UroGen’s RTGel technology and anchors the company’s commercial presence in bladder cancer.
Next-Generation Mitomycin Programs
UGN-103 is a next-generation mitomycin formulation for recurrent low-grade intermediate-risk NMIBC and is advancing toward an NDA based on the Phase 3 UTOPIA trial. UGN-104 applies a related formulation strategy to low-grade upper tract urothelial carcinoma and is being studied in an ongoing Phase 3 trial.
Oncolytic Virus Expansion
UGN-501 is an investigational next-generation oncolytic virus initially planned for intravesical administration in NMIBC. The company also intends to evaluate delivery with RTGel, potentially extending local exposure and activity.
未來催化劑
- Six-month durability data for UGN-103 expected in mid-2026.
- UGN-501 IND submission planned for the second quarter of 2026, followed by Phase 1 initiation by year-end.
- UGN-103 NDA submission planned for the second half of 2026.
- Completion of enrollment in the UGN-104 Phase 3 trial expected by year-end 2026.
近期新聞
- 01
- 02
- 03
- 04
- 05
相似股票
商業成熟度、治療領域或催化劑模式相近的同業公司。